期刊文献+

复方丹参注射液联合硫酸镁治疗对子痫前期患者血压与尿蛋白含量的影响 被引量:6

Effect of Danshen Injection Combined Magnesium Sulfate on Blood Pressure and Urine Protein Levels in Patients with Preeclampsia
暂未订购
导出
摘要 目的:探讨复方丹参注射液联合硫酸镁治疗子痫前期的临床疗效。方法:选取笔者所在医院收治的子痫前期孕妇216例作为研究对象,对照组108患者给予硫酸镁降压治疗,试验组108例患者在此基础上加用复方丹参注射液联合治疗。对比两组患者血压、尿蛋白含量变化及治疗效果。结果:试验组总有效率(95.4%)明显高于对照组,差异有统计学意义(字2=17.755,P<0.05);治疗后试验组平均动脉压(90.5±24.2)mm Hg,24 h尿蛋白含量(323.1±31.4)mg,明显低于对照组,差异有统计学意义(P<0.05)。结论:复方丹参注射液联合硫酸镁治疗子痫前期,降血压、降低尿蛋白效果理想,不良反应较少,值得临床推广应用。 Objective:To investigate the clinical efficacy of Danshen injection combined with magnesium sulfate therapy in patients with preeclampsia. Method:216 pregnant women with preeclampsia in our hospital were as the research object,108 patients in the control group were given magnesium sulfate antihypertensive treatment,the other 108 patients in the treatment group were given Danshen injection based on the use of magnesium sulfate.Blood pressure, urine protein in two groups of patients and the treatment effect were compared.Result:The total efficiency of the treatment group was 95.4%,significantly higher than that in the control group(χ2=17.755,P〈0.05).After treatment,mean arterial pressure was (90.5±24.2)mm Hg in the treatment group,24 h urine protein levels was(323.1±31.4)mg,significantly lower than that in the control group(P〈0.05).Conclusion:Danshen injection combined with magnesium sulfate for treatment of preeclampsia,can lower blood pressure,reduce urinary protein,has fewer side effects,is worthy of clinical application.
作者 温健中
出处 《中外医学研究》 2014年第11期12-13,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 复方丹参注射液 硫酸镁 子痫前期 Danshen injection Magnesium sulfate Preeclampsia
  • 相关文献

参考文献6

二级参考文献41

  • 1冯欣,于洁,孙定人.妊娠高血压综合征药物治疗现状[J].中国药房,2005,16(6):471-473. 被引量:12
  • 2胡志德,徐胜,胡川闽.一氧化氮与正常妊娠及妊高征的关系研究进展[J].国外医学(临床生物化学与检验学分册),2005,26(7):438-440. 被引量:2
  • 3彭波.联合用药治疗妊高症136例临床疗效观察[J].地方病通报,2006,21(6):113-113. 被引量:9
  • 4刘红秀.妊娠高血压综合征临床治疗研究[J].临床和实验医学杂志,2007,6(5):82-83. 被引量:10
  • 5李莉 丛林 陈珊珊.早发性先兆子痫母儿结局的86例临床分析.中国优生优育,2008,14(2):74-76.
  • 6HaddadB,DeisS,GoffinetF,eta1.Maternalandperinataloutcomesduringexpectantmanagementof239sevelpre-eclampticwomenbetween24and33weeks gestation[J].AmJObstetGynecol,2004,190(6):1590-1597.
  • 7Mutter WP, Karumanchi SA. Molecularmechanisms of pre-eclampsia [J ]. Microvasc Res,2008,75 ( i ) : 1-8.
  • 8Horvath JS, Korda A, Chid A, et al. Hypertension in pregnancy: a study of 142 women presenting before 32 weeks' gestation[J]. Med J,1985,143(1) :19.
  • 9Abramovici D, Friedman SA, Mercer BM, et al. Neonatal outcome insevere pre-eclampsia at 24 to 36 weeks of geslation: does the HELLP syndrome matter [ J ]. Am J Obstet Gyneeol, 1999, 180 (28) :221.
  • 10乐杰.妇产科学[M].6版.北京:人民卫生出版社,2002:22

共引文献127

同被引文献52

  • 1范翠芳,乔福元,宋梅.小剂量阿斯匹林预防先兆子痫[J].中国优生与遗传杂志,2005,13(5):68-69. 被引量:12
  • 2王吉耀.内科学[M].北京:人民卫生出版社,2006:575—580.
  • 3王思宝,张定凤,主编.现代肝脏病学[M].北京:科学出版社,2003.184-185.
  • 4乐杰.妇产科学[M].第7版.北京:人民卫生出版社,2007:6
  • 5Society of obstetricians and gynaecologists of Canada SOGC clinic practice guidelines.The detection and management of vaginal atrophy[J].Int J Gtnaecol Obstet,2005,88(2):222-228.
  • 6Zhuang Y,Zhu X,Huang L.Antispasmodics and anticholinergies.In:Neeshat QM,editor.Pharmaguide[M].16th ed.Karachi:Pharmaguide publishing company,2003:66-70.
  • 7Jabeen M,Yakoob M Y,Imdad A,et al.Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirth[J].BMC Publish Health,2001,12(Suppl 3):S3.
  • 8Vadnais MA, Rana S, Quant HS, et al. The Impact of Magnesium Sulfate Therapy on Angiogenic Factors in Preeclampsia [ J ]. Pregnancy Hyper- tens,2012,2( 1 ) :16 -21.
  • 9Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 ( sFltl ) may contribute to endothelial dysfunction, hy- pertension, and proteinuria in preeclampsia[ J ]. J Clin Invest,2003,111 (5) :649 -658.
  • 10徐卫东.早发型重度子痫前期期待治疗研究现状[J].医学理论与实践,2009,22(5):539-541. 被引量:9

引证文献6

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部